Anyone already receiving a GLP-1 through Part D does not qualify, and neither do patients with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease, since those conditions can open a separate coverage path
The growth is driven by expanding therapeutic applications beyond diabetes, such as obesity and cardiovascular diseases
Over the past few years, GLP-1 medications have fundamentally changed how we think about metabolic health
GLP-1 medications can help: Weight loss from these medications reduces sleep apnea severity Studies show they can reduce the Apnea-Hypopnea Index (AHI) by 12-15 events per hour Tirzepatide reduced AHI by 48-56% compared to placebo Since OSA is both a cause and consequence of other health problems, improving sleep breathing can create a cascade of health benefits
Over 72 weeks, the 15 mg dose delivered a mean weight reduction of about 20.9%, and the 10 mg dose about 19.5%